The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world experience and molecular features of response to immune checkpoint blockade in patients with recurrent small cell lung cancer.
 
Wei-Chu Victoria Lai
Consulting or Advisory Role - PharmaMar
 
Hira Rizvi
No Relationships to Disclose
 
Jacklynn V. Egger
No Relationships to Disclose
 
Andrew J. Plodkowski
No Relationships to Disclose
 
Michelle S. Ginsberg
No Relationships to Disclose
 
Mark G. Kris
Consulting or Advisory Role - AstraZeneca; Pfizer; Regeneron
Travel, Accommodations, Expenses - AstraZeneca
Other Relationship - Memorial Sloan-Kettering Cancer Center
 
Amanda Beras
No Relationships to Disclose
 
Natasha Rekhtman
No Relationships to Disclose
 
John T. Poirier
Research Funding - Abbvie/Stemcentrx (Inst); Daiichi Sankyo (Inst); Merck (Inst); Viralytics (Inst)
Patents, Royalties, Other Intellectual Property - SLFN11 measurement by mass spectrometry; SVV receptor directed therapy
 
Matthew David Hellmann
Stock and Other Ownership Interests - Shattuck Labs
Honoraria - AstraZeneca; Bristol-Myers Squibb
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech; Janssen; Merck; Mirati Therapeutics; Nektar; Novartis; Shattuck Labs; Syndax
Research Funding - Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - A patent has been filed by Memorial Sloan Kettering (PCT/US2015/062208) for the use of tumor mutation burden for prediction of immunotherapy efficacy, and which is licensed to Personal Genome Diagnostics. (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb
 
Charles M. Rudin
Consulting or Advisory Role - Abbvie; Ascentage Pharma; AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Daiichi Sankyo; Elucida Oncology; Genentech/Roche; Harpoon Therapeutics; Ipsen; Loxo; PharmaMar; PharmaMar; Seagen
Research Funding - Abbvie/Stemcentrx (Inst); Daiichi Sankyo (Inst); Merck (Inst); Viralytics (Inst)